CuraGen Corp. and Abgenix Inc. said they have identified two dozen cancer-drug targets for evaluation and possible use in the development of therapeutic antibodies under a five-year collaboration that began late last year.

The companies said that antibodies against the 24 targets would be tested for efficacy in preclinical studies starting later this year. Antibodies with the best potential, the companies said, could be in clinical...